Skip to content

<img width="204" height="84" src="https://www.umoja-biopharma.com/wp-content/uploads/2022/06/Umoja-Biopharma.svg" class="custom-logo astra-logo-svg" alt="Umoja Biopharma" decoding="async" />

Our Company
Our Science
Our Pipeline
News + Resources
Careers
Contact

Our Company
- Our Team
Our Science
Our Pipeline
News + Resources
Careers
Contact

<img width="204" height="84" src="https://www.umoja-biopharma.com/wp-content/uploads/2022/06/Umoja-Biopharma.svg" class="custom-logo astra-logo-svg" alt="Umoja Biopharma" decoding="async" />

Our Company
- Our Team
Our Science
Our Pipeline
News + Resources
Careers
Contact

Accessibility
Privacy Policy
Transparency in Coverage
Sitemap

Presentations + Publications

Search presentations

Publication

Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering

Journal for ImmunoTherapy of Cancer

March 16, 2023

Presentation

Synthetic Receptor Enabled Differentiation (ShRED), a novel platform for manufacturing of iPSC-derived cytotoxic innate lymphocytes for “off-the-shelf” cancer immunotherapies

November 11, 2022

Presentation

VivoVec lentiviral vector particles surface-engineered with T cell activating and co-stimulatory ligands enhance in vivo CAR T cell generation and antitumor activity

November 11, 2022

Presentation

In vivo generation of universal CAR T cells that mediate durable anti-tumor immunity through combinatorial targeting with bispecific small molecule adaptors

November 10, 2022

Presentation

Engineering iPSCs with Synthetic Receptors to Drive Differentiation Compatible with Scale-Up

July 28, 2022

Our Company
Our Science
Manufacturing
Partnerships
Our Pipeline
Careers

Press Releases
In The Media
Blog
White Papers
Presentations

1616 Eastlake Ave E.
Suite 550
Seattle, WA 98102
info@umoja-biopharma.com

Accessibility
Privacy Policy
Transparency in Coverage
Sitemap

© 2023 Umoja Biopharma. All rights reserved.